Virtu KCG Holdings’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-25,800
Closed -$1.77M 2829
2015
Q4
$1.77M Sell
25,800
-4,900
-16% -$324K 0.03% 477
2015
Q3
$1.82M Buy
30,700
+9,100
+42% +$577K 0.03% 501
2015
Q2
$1.44M Buy
+21,600
New +$1.42M 0.03% 599
2015
Q1
Sell
-36,700
Closed -$2.17M 3169
2014
Q4
$2.17M Buy
36,700
+21,900
+148% +$1.24M 0.04% 398
2014
Q3
$757K Sell
14,800
-33,100
-69% -$1.65M 0.01% 1244
2014
Q2
$2.32M Sell
47,900
-64,500
-57% -$3.18M 0.04% 452
2014
Q1
$5.84M Buy
112,400
+11,500
+11% +$612K 0.07% 217
2013
Q4
$5.36M Sell
100,900
-23,300
-19% -$1.19M 0.06% 215
2013
Q3
$5.75M Buy
+124,200
New +$5.45M 0.07% 188

Other funds holding BMY

Virtu KCG Holdings's BMY Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Bristol-Myers Squibb (BMY) stake by 71% in Q2 2017, selling an estimated $2.99M and leaving 22,205 shares worth $1.24M. The position accounts for 0.03% of the portfolio, ranked #463.

Virtu KCG Holdings first reported a position in BMY in Q3 2013 and has held it in 16 quarters since. The position peaked at $5.84M in Q1 2015. 1,594 funds tracked by Wall St. Rank hold BMY as of Q2 2017.

  • Virtu KCG Holdings held 22,205 shares of Bristol-Myers Squibb worth $1.24M as of Q2 2017.
  • Virtu KCG Holdings sold 54,994 Bristol-Myers Squibb shares in Q2 2017, an estimated $2.99M.
  • Bristol-Myers Squibb made up 0.03% of Virtu KCG Holdings's portfolio in Q2 2017, its #463 holding.
  • Virtu KCG Holdings first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 16 quarters since.
  • Virtu KCG Holdings's Bristol-Myers Squibb position peaked at $5.84M in Q1 2015.
  • 1,594 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.